IX Biopharma Ltd
SGX:42C
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IX Biopharma Ltd
Total Current Liabilities
IX Biopharma Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Total Current Liabilities
S$8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Total Current Liabilities
$95.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
38%
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Total Current Liabilities
S$126m
|
CAGR 3-Years
8%
|
CAGR 5-Years
15%
|
CAGR 10-Years
1%
|
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Total Current Liabilities
S$49.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
IX Biopharma Ltd
Glance View
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
See Also
What is IX Biopharma Ltd's Total Current Liabilities?
Total Current Liabilities
8m
SGD
Based on the financial report for Dec 31, 2025, IX Biopharma Ltd's Total Current Liabilities amounts to 8m SGD.
What is IX Biopharma Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
23%
Over the last year, the Total Current Liabilities growth was 11%. The average annual Total Current Liabilities growth rates for IX Biopharma Ltd have been 1% over the past three years , 23% over the past five years .
